SCHEMBL5063159

SCHEMBL5063159

Cc1nc(N)sc1-c1cccc(S(=O)(=O)CF)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 1/20 0.43
CDK1 P06493 1/20 0.43
CCNB1 P14635 1/20 0.43
CCNA2 P20248 1/20 0.43
CDK2 P24941 1/20 0.43
CDK7 P50613 1/20 0.43
CDK9 P50750 1/20 0.43
CCNH P51946 1/20 0.43
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
HRH2 P25021 5/20 0.41
HRH1 P35367 5/20 0.41
HRH4 Q9H3N8 5/20 0.41
HRH3 Q9Y5N1 5/20 0.41
GFER P55789 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3C3 Q8NEB9 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
GAA P10253 1/20 0.37
NR1H2 P55055 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27597046 0.84 LOXL2 (0.47) CCNT1CDK1CCNB1CCNA2CDK2
SCHEMBL5063157 0.83 GPR52 (0.41) MEN1KMT2AHRH2HRH1HRH4
Bromide SCHEMBL49028 0.83 LOXL2 (0.46) CCNT1CDK1CCNB1CCNA2CDK2
SCHEMBL8084192 0.75 MAPT (0.51) MEN1KMT2AHRH2HRH1HRH4
SCHEMBL8083511 0.74 MEN1 (0.54) MEN1KMT2AL3MBTL1GAAALDH1A1
SCHEMBL2073010 0.72 PIK3CD (0.42) PIK3CAALDH1A1NPC1
SCHEMBL9953765 0.72 TGFBR1 (0.48) MEN1KMT2AHRH2HRH1HRH4
SCHEMBL28357067 0.72 MAPT (0.51) MEN1KMT2AHRH2HRH1HRH4
SCHEMBL330359 0.71 BRD4 (0.51) HRH2HRH1HRH4HRH3ALDH1A1
SCHEMBL15651211 0.71 BRD4 (0.47) MEN1KMT2AHRH2HRH1HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080280871-A1 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases NOVARTIS AG (CH) 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280871-A1 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases PI4KA, IP6K3, PHOSPHO1 CCNT1 2154/4885CDK1 574/4885CCNB1 1506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.